Phase 4 Rheumatoid Arthritis Trial, Recruiting NCT06527534 Sponsor: Universita di Verona Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 4 Rheumatoid Arthritis Trial, Recruiting

NCT06527534
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Rheumatoid Arthritis (RA) according to specific medical guidelines, and whose disease is currently considered active based on standard scoring measurements
  • People who are older than 18 and younger than 65 years of age
  • People for whom a doctor has considered treatment with filgotinib or adalimumab (two specific medications used for Rheumatoid Arthritis)

Who may not be able to join:

  • People who have a history of major heart problems or stroke
  • People who have previously had blood clots in their veins (such as deep vein thrombosis or pulmonary embolism)
  • People who currently smoke, or people who smoked heavily in the past (more than 10 pack-years, which refers to smoking one pack of cigarettes per day for 10 years, or an equivalent amount)
  • People who have had bone fractures caused by weakened bones, or who have been diagnosed with severe osteoporosis based on specific bone density measurements
  • People who are currently taking certain bone-related medications, including estrogens, bisphosphonates, denosumab, teriparatide, or romosozumab
  • People who have been taking moderate to high doses of steroid medications (such as prednisone at 7.5 mg per day or more) for longer than 3 months before joining the trial (confirm with trial site for details about shorter-term steroid use)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +390458122574

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Universita di Verona
Registry
ClinicalTrials.gov
Start date
15 July 2024
Est. completion
15 July 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

micro RNA (miRNA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov